Literature DB >> 20170812

Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation.

Daniela Husser1, Volker Adams, Christopher Piorkowski, Gerhard Hindricks, Andreas Bollmann.   

Abstract

OBJECTIVES: This study tested the hypothesis that chromosome 4q25 single-nucleotide polymorphisms (SNPs) associate with atrial fibrillation (AF) recurrence after catheter ablation.
BACKGROUND: Recent genome-wide association studies identified 2 SNPs on chromosome 4q25 associated with AF. Although the mechanisms underlying this increased risk are unknown, the closest gene, PITX2, is critical for myocardium development in the pulmonary veins.
METHODS: A total of 195 consecutive patients (mean age 56 +/- 12 years, 73% male) with drug-refractory paroxysmal (78%) or persistent (22%) AF who underwent AF catheter ablation were included. Two SNPs, rs2200733 and rs10033464, were genotyped using real-time polymerase chain reaction and fluorescence resonance energy transfer. Serial 7-day Holter electrocardiographic recordings were acquired to detect AF recurrences.
RESULTS: Early recurrence of atrial fibrillation (ERAF) (within the first 7 days) was observed in 37%, whereas late recurrence of atrial fibrillation (LRAF) (between 3 and 6 months) occurred in 21% of the patients. None of the clinical or echocardiographic baseline characteristics were associated with ERAF or LRAF. In contrast, the presence of any variant allele increased the risk for both ERAF (odds ratio [OR]: 1.994, 95% confidence interval [CI]: 1.036 to 3.837, p = 0.039) and LRAF (OR: 4.182, 95% CI: 1.318 to 12.664, p = 0.011). In patients with ERAF, 45% had LRAF, as opposed to 8% in patients without ERAF (OR: 9.274, 95% CI: 3.793 to 22.678, p < 0.001).
CONCLUSIONS: Polymorphisms on chromosome 4q25 modulate the risk for AF recurrence after catheter ablation. This finding points to a potential role for stratification of AF ablation therapy or peri-interventional management by genotype. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20170812     DOI: 10.1016/j.jacc.2009.11.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  81 in total

1.  Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification.

Authors:  Jun Wang; Elzbieta Klysik; Subeena Sood; Randy L Johnson; Xander H T Wehrens; James F Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation.

Authors:  Babar Parvez; Joseph Vaglio; Shane Rowan; Raafia Muhammad; Gayle Kucera; Tanya Stubblefield; Shannon Carter; Dan Roden; Dawood Darbar
Journal:  J Am Coll Cardiol       Date:  2012-06-20       Impact factor: 24.094

Review 3.  Genome-wide association studies of late-onset cardiovascular disease.

Authors:  J Gustav Smith; Christopher Newton-Cheh
Journal:  J Mol Cell Cardiol       Date:  2015-04-11       Impact factor: 5.000

Review 4.  Emerging directions in the genetics of atrial fibrillation.

Authors:  Nathan R Tucker; Patrick T Ellinor
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

5.  Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation.

Authors:  M Benjamin Shoemaker; Daniela Husser; Carolina Roselli; Meelad Al Jazairi; Jonathan Chrispin; Michael Kühne; Benjamin Neumann; Stacey Knight; Han Sun; Sanghamitra Mohanty; Christian Shaffer; Sébastien Thériault; Lauren Lee Rinke; Joylene E Siland; Diane M Crawford; Laura Ueberham; Omeed Zardkoohi; Petra Büttner; Bastiaan Geelhoed; Steffen Blum; Stefanie Aeschbacher; Jonathan D Smith; David R Van Wagoner; Rebecca Freudling; Martina Müller-Nurasyid; Jay Montgomery; Zachary Yoneda; Quinn Wells; Tariq Issa; Peter Weeke; Victoria Jacobs; Isabelle C Van Gelder; Gerhard Hindricks; John Barnard; Hugh Calkins; Dawood Darbar; Greg Michaud; Stefan Kääb; Patrick Ellinor; Andrea Natale; Mina Chung; Saman Nazarian; Michael J Cutler; Moritz F Sinner; David Conen; Michiel Rienstra; Andreas Bollmann; Dan M Roden; Steven Lubitz
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-02-14

Review 6.  The Genetic Basis of Coronary Artery Disease and Atrial Fibrillation: A Search for Disease Mechanisms and Therapeutic Targets.

Authors:  Jacques Neelankavil; Christoph D Rau; Yibin Wang
Journal:  J Cardiothorac Vasc Anesth       Date:  2015-01-23       Impact factor: 2.628

Review 7.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 8.  Common variants for atrial fibrillation: results from genome-wide association studies.

Authors:  Xinyuan Liu; Fei Wang; Ashley C Knight; Jiangmin Zhao; Junjie Xiao
Journal:  Hum Genet       Date:  2011-07-07       Impact factor: 4.132

9.  Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion.

Authors:  Babar Parvez; M Benjamin Shoemaker; Raafia Muhammad; Rachael Richardson; Lan Jiang; Marcia A Blair; Dan M Roden; Dawood Darbar
Journal:  Heart Rhythm       Date:  2013-02-19       Impact factor: 6.343

Review 10.  New advances in the genetic basis of atrial fibrillation.

Authors:  Saagar Mahida; Patrick T Ellinor
Journal:  J Cardiovasc Electrophysiol       Date:  2012-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.